Last Updated: July 27, 2026

Claims for Patent: 10,626,154

✉ Email this page to a colleague

Summary for Patent: 10,626,154

Title:	Binding domains directed against GPCR:G protein complexes and uses derived thereof
Abstract:	The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.
Inventor(s):	Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Soren G. F. Rasmussen, Sebastien Granier, Roger K. Sunahara
Assignee:	Vlaams Instituut voor Biotechnologie VIB , Vrije Universiteit Brussel VUB , University of Michigan System , Leland Stanford Junior University
Application Number:	US15/583,540

Details for Patent 10,626,154

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444	March 28, 2014	10,626,154	2037-05-01
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444	February 18, 2016	10,626,154	2037-05-01
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444	July 14, 2016	10,626,154	2037-05-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,626,154

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012175643	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2013063343	⤷ Start Trial
United States of America	12252521	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.